22.02.2021 | ASO Author Reflections
ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead to Improved Survival in All Patients
verfasst von:
Elizabeth J. Olecki, MD, Niraj J. Gusani, MD, MS, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 6/2021
Einloggen, um Zugang zu erhalten
Excerpt
While landmark trials have established that treatment of early stage pancreatic cancer should include both local and systemic therapy,
1,
2 the ideal sequence of surgery and chemotherapy remains unknown, especially regarding the role of neoadjuvant chemotherapy (NT). Additionally, no high-level evidence currently exists regarding use of adjuvant chemotherapy (AT) after completion of NT and surgical resection, leaving the decision to pursue AT in this growing group of patients to the discretion of individual clinicians without guidance regarding which patients may benefit from additional AT.
3 …